MATW-PROJECT
28.11.2022 12:12:36 CET | Business Wire | Press release
The ‘Muslims Around the World Project’ (MATW-Project), a new-generation non-governmental organization building heritage with global impact, was founded by Ali Banat, who passed away from cancer at a young age. To acknowledge his contribution, TRT World Citizen Awards, an organization that honors people who contribute greatly to society, has granted Ali Banat its Lifetime Achievement Award. Mahmoud Ismail, Ali Banat's friend and the CEO of MATW-Project, received the award at the ceremony in Istanbul on November 25 from TRT World, the international English language broadcaster operated by Turkiye's national broadcaster TRT.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005245/en/
CEO of MATW-Project Mahmoud Ismail and TRT Director General Prof. Zahid Sobacı (Photo: Business Wire)
Ali Banat was an Arab-Australian businessperson who owned a security and electrical company and died in 2018, following a struggle with cancer. Following his cancer diagnosis in October 2015, Ali Banat donated all his wealth to charity and founded MATW-Project.
Mahmoud Ismail expressed his thoughts about the award, saying, "We lost Ali Banat but his legacy lives on in what he did for the world and for charity. His MATW-Project, based in Australia, carries on its business with a strong presence in many countries worldwide, especially in Africa. We would like to thank TRT World for recognizing the contributions of MATW to the world and granting this award to our founder Ali Banat."
This year, the TRT World Citizen Awards held its award ceremonies for the third time. The ceremony was attended by many international people from different parts of society, such as politics, academia, arts, entertainment, humanitarian aid, and business.
This non-profit organization cherishes Ali Banat's legacy and contributes to positive change worldwide. With its 774,000 supporters on social media, the MATW-Project has built more than 950 water wells in Africa to make up for the water shortage, supported more than 1,000 orphan children and touched the lives of more than 3 million people.
The MATW-Project operates on a 100% donation basis, meaning that every donated amount is given to those in need, and provides humanitarian support in countries such as Bangladesh, Pakistan, Palestine, Yemen, Syria, and Afghanistan. It also provides shelter, access to water, education and guidance services in challenging living conditions.
Explaining that they want to maximize the impact of donations through a sustainable model, Ismail concluded his speech: "At the MATW-Project, we strive to build equitable and fair living conditions compatible with human dignity; inspired by our values of reliability, efficiency, sustainability, impact, and belief. I hope that this Lifetime Achievement Award from TRT World to our Founder Ali Banat will help further raise awareness of the MATW-Project's activities by reaching more people around the globe."
Visit us at https://matwproject.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005245/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom